Immunotherapy in ovarian cancer.
Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.
Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California.
Venkatesh
V
Krishnan
Department of Obstetrics and Gynecology, Stanford Women׳s Cancer Center, Stanford University School of Medicine, Stanford, California.
Jonathan S
JS
Berek
Department of Obstetrics and Gynecology, Stanford Women׳s Cancer Center, Stanford University School of Medicine, Stanford, California. Electronic address: odorigo@stanford.edu.
Oliver
O
Dorigo
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D059447:Cell Cycle Checkpoints / Q000276:immunology; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D016219:Immunotherapy, Adoptive / Q000379:methods; D058990:Molecular Targeted Therapy / Q000379:methods; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines
Immunotherapy; ovarian cancer